Lifeward Ltd. (LFWD)

NCM – Real Time Price. Currency in USD

7.20

+0.33 (4.80%)

At close: Jun 26, 2026, 4:00 PM EDT

7.25

+0.05 (0.69%)

After-hours: Jun 26, 2026, 4:21 PM EDT

19.05.2026

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic disease

15.05.2026

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

15.05.2026

Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates

Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $5.52 per share a year ago.

15.05.2026

Lifeward Reports First Quarter 2026 Financial Results

Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in o perating expenses and cash utilization as company prepares to scale neurorehabilit ati on products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass.

11.05.2026

Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026.

04.05.2026

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient profiles and bone health conditions Findings reinforce safety profile and support expanded adoption of ReWalk for spinal c ord injury mobility Lifeward CEO Mark Gr ant addressed the 53 rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people living with spinal cord injuries HUDSON, Mass., and YOKNEAM ILLIT, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

25.03.2026

Lifeward Successfully Closes on Strategic Partnership with Oramed

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Videos

No Data

There is no data to display

Press releases

19.05.2026

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

15.05.2026

Lifeward Reports First Quarter 2026 Financial Results

04.05.2026

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

25.03.2026

Lifeward Successfully Closes on Strategic Partnership with Oramed

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Ltd. (LFWD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lifeward Ltd. (LFWD)

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates

Lifeward Reports First Quarter 2026 Financial Results

Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed

Videos

No Data

Press releases

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Reports First Quarter 2026 Financial Results

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates

Lifeward Reports First Quarter 2026 Financial Results

Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed

Videos

No Data

Press releases

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Reports First Quarter 2026 Financial Results

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed

Search stocks

Lifeward Ltd. (LFWD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lifeward Ltd. (LFWD)

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates

Lifeward Reports First Quarter 2026 Financial Results

Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed

Videos

No Data

Press releases

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Reports First Quarter 2026 Financial Results

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates

Lifeward Reports First Quarter 2026 Financial Results

Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed

Videos

No Data

Press releases

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Lifeward Reports First Quarter 2026 Financial Results

Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton

Lifeward Successfully Closes on Strategic Partnership with Oramed